Quarterly ResultAug 13, 2026, 05:00 PM
BIO-key Q2 Net Loss Halved to $576K; Revenue Up 13%
AI Summary
BIO-key International reported a significant reduction in net loss for Q2 2026, halving to $(576,852) from $(1,167,396) in the prior year, while total revenues grew by 13.1% to $1,919,991. Despite these improvements, the company issued a going concern warning due to historical losses and negative cash flow, with cash and cash equivalents decreasing to $1,379,300. A 1-for-10 reverse stock split was effective April 30, 2026, and an equity investment in Boumarang, Inc. maintains a 50% impairment.
Key Highlights
- Q2 2026 net loss decreased by 50.6% to $(576,852) from $(1,167,396) in Q2 2025.
- Q2 2026 total revenues increased by 13.1% to $1,919,991 from $1,696,907 in Q2 2025.
- H1 2026 net loss decreased by 58.9% to $(781,889) from $(1,903,941) in H1 2025.
- H1 2026 total revenues increased by 23.0% to $4,065,524 from $3,304,066 in H1 2025.
- Cash and cash equivalents decreased to $1,379,300 as of June 30, 2026, from $2,694,663.
- Company issued a going concern warning due to historical losses and negative cash flow.
- A 1-for-10 reverse stock split was effective April 30, 2026, retrospectively adjusted.
- Equity investment in Boumarang, Inc. remains at $2,500,000 with a 50% impairment.
Price Impact
More from BKYI